PriceTargets.com logo

Creo Medical Group - CREO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 100
  • Forecasted Upside: 304.86%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 24.70 As of 03/30/2023 01:00 AM ET
▼ -0.15 (-0.60%)

This chart shows the closing price for CREO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Creo Medical Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CREO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CREO

Analyst Price Target is GBX 100
▲ +304.86% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Creo Medical Group in the last 3 months. The average price target is GBX 100, with a high forecast of GBX 100 and a low forecast of GBX 100. The average price target represents a 304.86% upside from the last price of GBX 24.70.

This chart shows the closing price for CREO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Creo Medical Group.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/17/2023Numis SecuritiesReiterated RatingBuyGBX 100
(Data available from 3/30/2018 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Creo Medical Group logo
Creo Medical Group PLC, through its subsidiaries, engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal devices to optimize treatments for patients and physicians. The company also offers Speedboat Inject, an energy multimodality instrument for flexible endoscopy; Speedboat Slim, a flexible bipolar RF and microwave device for cutting and coagulation; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highlyperfused tissues; and endotherapy accessories. Creo Medical Group PLC was founded in 2003 and is based in Chepstow, United Kingdom.
Read More

Today's Range

Now: GBX 24.70
Low: 24.53
High: 25

50 Day Range

MA: GBX 24.56
Low: 19
High: 34.75

52 Week Range

Now: GBX 24.70
Low: 19
High: 113.25

Volume

189,714 shs

Average Volume

789,744 shs

Market Capitalization

£86.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Creo Medical Group?

The following equities research analysts have issued reports on Creo Medical Group in the last twelve months: Numis Securities Ltd.
View the latest analyst ratings for CREO.

What is the current price target for Creo Medical Group?

1 Wall Street analysts have set twelve-month price targets for Creo Medical Group in the last year. Their average twelve-month price target is GBX 100, suggesting a possible upside of 304.9%. Numis Securities Ltd has the highest price target set, predicting CREO will reach GBX 100 in the next twelve months. Numis Securities Ltd has the lowest price target set, forecasting a price of GBX 100 for Creo Medical Group in the next year.
View the latest price targets for CREO.

What is the current consensus analyst rating for Creo Medical Group?

Creo Medical Group currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CREO will outperform the market and that investors should add to their positions of Creo Medical Group.
View the latest ratings for CREO.

What other companies compete with Creo Medical Group?

Other companies that are similar to Creo Medical Group include Polarean Imaging, Belluscura, Inspiration Healthcare Group, Kromek Group and Intelligent Ultrasound Group. Learn More about companies similar to Creo Medical Group.

How do I contact Creo Medical Group's investor relations team?

The company's listed phone number is +44-1291-606005. The official website for Creo Medical Group is creomedical.com. Learn More about contacing Creo Medical Group investor relations.